Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.
Authors
- Kristin Tolksdorf (ORCID: https://orcid.org/0000-0002-8712-6399)
- Mihaela Lazăr (ORCID: https://orcid.org/0000-0002-8226-6026)
- Jesús Castilla
- Petr Husa (ORCID: https://orcid.org/0000-0002-9190-2610)
- Verónica Gomez (ORCID: https://orcid.org/0000-0003-0485-0005)
- Liliana Antunes (ORCID: https://orcid.org/0000-0003-0453-5304)
- Zvjezdana Lovrić Makarić (ORCID: https://orcid.org/0000-0003-4285-2116)
- Terra Fatukasi (ORCID: https://orcid.org/0000-0003-3287-1831)
- Gergő Túri (ORCID: https://orcid.org/0000-0003-3465-8321)
- Goranka Petrović (ORCID: https://orcid.org/0000-0001-8304-5519)
- Maria‐Louise Borg (ORCID: https://orcid.org/0000-0001-8961-9413)
- Gloria Pérez‐Gimeno (ORCID: https://orcid.org/0000-0003-3435-4854)
- Alexandru Marin (ORCID: https://orcid.org/0009-0000-7668-9607)
- Lenka Součková (ORCID: https://orcid.org/0000-0003-0028-4464)
- Aryse Melo (ORCID: https://orcid.org/0000-0002-6655-8715)
- Beatrix Oroszi (ORCID: https://orcid.org/0000-0001-8915-0336)
- Aušra Džiugytė (ORCID: https://orcid.org/0000-0003-0486-8491)
- Ralf Dürrwald (ORCID: https://orcid.org/0000-0002-3432-0438)
- Ausenda Machado (ORCID: https://orcid.org/0000-0002-1849-1499)
- Nathalie Nicolay (ORCID: https://orcid.org/0000-0002-5916-7855)
- Jennifer Howard (ORCID: https://orcid.org/0009-0008-1930-8693)
- Angela MC Rose (ORCID: https://orcid.org/0000-0002-2493-8082)
- Reinout Naesens (ORCID: https://orcid.org/0000-0003-1004-7737)
- Auksė Mickienė (ORCID: https://orcid.org/0000-0002-4998-1319)
- Ligita Jančorienė (ORCID: https://orcid.org/0000-0001-6488-6312)
- Clara Mazagatos (ORCID: https://orcid.org/0000-0002-6909-6923)
- Margaret G. Fitzgerald (ORCID: https://orcid.org/0000-0002-4535-0966)
- Eva Bernaert
- Iván Martínez‐Baz (ORCID: https://orcid.org/0000-0002-3405-2277)
Institutions
- Semmelweis University (HU)
- Lithuanian University of Health Sciences (LT)
- Vilnius University (LT)
- Masaryk University (CZ)
- Robert Koch Institute (DE)
- Instituto de Salud Carlos III (ES)
- Health Service Executive (IE)
- Instituto de Salud Pública de Navarra (ES)
- Hrvatski zavod za javno zdravstvo (HR)
- University Hospital Brno (CZ)
- Institutul Cantacuzino (RO)
- Health Protection Surveillance Centre (IE)
- Spitalul Clinic Dr. Victor Babes (RO)
- National Institute of Health Dr. Ricardo Jorge (PT)
- Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES)
- European Centre for Disease Prevention and Control (SE)
Publication Details
- Journal
- Influenza and Other Respiratory Viruses
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1111/irv.13360
- Citations
- 11
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 4.28
Funders
- European Centre for Disease Prevention and Control